Resistance to MEK inhibition due to the upregulation of STAT3 signaling has been well documented in a number of cancers including melanoma28,29, low-grade gliomas43, colon44, pancreatic45, thyroid30, lung46, and breast cancer31. Here, MAP2K7 is linked to cancer.